Literature DB >> 12766380

Gabapentin for the treatment of ethanol withdrawal.

John Voris1, Nancy L Smith, Subba M Rao, Diana L Thorne, Queen J Flowers.   

Abstract

Benzodiazepines (BZDs) are the drug of choice for the suppression of alcohol withdrawal symptoms. Gabapentin, a drug approved for use as adjunctive therapy in the treatment of partial seizures, has none of the BZD-type difficulties (drug interactions, abuse potential). We retrospectively report on the use of gabapentin for ethanol withdrawal in 49 patients. Thirty-one patients were treated in the outpatient program and 18 in the general inpatient psychiatric unit. Positive outcomes as evidenced by completion of gabapentin therapy were achieved in 25 out of 31 outpatients and 17 out of 18 inpatients. Statistical significance was reached regarding the positive relationship between prior ethanol use and inpatient "as needed" benzodiazepine use. Both sets of data suggest that gabapentin works well for the mild to moderate alcohol withdrawal patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766380     DOI: 10.1080/08897070309511541

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  17 in total

Review 1.  Identification and management of alcohol withdrawal syndrome.

Authors:  Antonio Mirijello; Cristina D'Angelo; Anna Ferrulli; Gabriele Vassallo; Mariangela Antonelli; Fabio Caputo; Lorenzo Leggio; Antonio Gasbarrini; Giovanni Addolorato
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

2.  Update on the neurobiology of alcohol withdrawal seizures.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2005 Nov-Dec       Impact factor: 7.500

3.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

Review 4.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

Review 5.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

6.  A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.

Authors:  Kirk J Brower; Hyungjin Myra Kim; Stephen Strobbe; Maher A Karam-Hage; Flavia Consens; Robert A Zucker
Journal:  Alcohol Clin Exp Res       Date:  2008-06-06       Impact factor: 3.455

7.  Cellular and behavioral interactions of gabapentin with alcohol dependence.

Authors:  Marisa Roberto; Nicholas W Gilpin; Laura E O'Dell; Maureen T Cruz; Andrew C Morse; George R Siggins; George F Koob
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

Review 8.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

Review 9.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

10.  A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.

Authors:  Hugh Myrick; Robert Malcolm; Patrick K Randall; Elizabeth Boyle; Raymond F Anton; Howard C Becker; Carrie L Randall
Journal:  Alcohol Clin Exp Res       Date:  2009-05-26       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.